Contents

STUDY/ELSE...

AI for Science across Big Tech

AI for Science across Big Tech: A 2025–26 Landscape

🤖 Researched & drafted with Claude (Anthropic) · organized and edited by the author

"AI for Science" covers so much ground now that the label barely tells you how differently each lab actually works. This post is a map: it sorts the major players by what they're really selling — a model, a drug, or an infrastructure layer — and links the flagship work behind each. Treat it as a hub; papers I read closely get their own posts, linked at the bottom.

00Three archetypes

A · Foundation labs

Build the models

DeepMind, Microsoft, Meta FAIR, ByteDance — structure prediction, generation, materials, and climate, shipped open or semi-open.

B · Discovery-first

Make the drugs

D. E. Shaw, Xaira, Isomorphic — physics simulation or large wet-lab loops that carry candidates all the way to the clinic.

C · Infrastructure

Lay the floor

NVIDIA BioNeMo — serving everyone else's models on GPUs, competing on the stack rather than the benchmark.

By domain, almost everyone starts in proteins and biology (structure, design, cells), then expands into molecules and materials (interatomic potentials, generative design), and in a few cases into climate.

01Google DeepMind & Isomorphic Labs

Google DeepMind & Isomorphic Labs

protein · genome · materials · climate
Flagship models
  • AlphaFold 3 — complexes of proteins with DNA, RNA, ligands, and ions (a diffusion module replaces AF2's structure module)
  • AlphaProteo — de novo binder design, 3–300× better affinity across seven targets
  • AlphaMissense for coding variants and AlphaGenome for the non-coding genome (1 Mb in, regulatory tracks out)
  • GNoME for crystals; GraphCast / GenCast for weather
Strategy

DeepMind treats AlphaFold as a template for bringing all of science "to digital speed." The commercial side is walled off: AlphaFold Server is free for academics, but the rights to use AlphaFold 3 commercially belong to Isomorphic Labs, its drug-discovery spinout, now working with Eli Lilly and Novartis.

One caveat — GNoME's headline count of predicted crystals is striking, but outside researchers have questioned how many are genuinely new or actually synthesizable. A large prediction count isn't the same as experimental value.

02Microsoft Research

Microsoft Research — AI for Science

materials · DFT · protein · climate
Flagship models
  • MatterGen — generates crystals conditioned on a target property; asked for 200 GPa bulk modulus, it produced TaCr₂O₆, later measured at 169 GPa
  • MatterSim and Skala — a universal interatomic potential, and a learned exchange–correlation functional for DFT itself
  • BioEmu — protein equilibrium ensembles, thousands per hour on a single GPU
  • Aurora — an atmospheric foundation model spanning weather, air quality, and ocean waves
Strategy

It spans more domains than any other lab, and ships most of it openly. The stated direction for 2026 is agentic "AI lab assistants" that propose hypotheses and help run the experiments.

Why BioEmu stands out — instead of a single static structure, it predicts a distribution of conformations, reconnecting structure prediction with dynamics and stability.

03Meta FAIR Chemistry

Meta FAIR — Chemistry

molecules · materials · catalysis
Flagship releases
  • OMol25 — over 100M DFT calculations, the largest molecular quantum-chemistry dataset to date
  • UMA — a single universal interatomic potential covering molecules, materials, and catalysts
  • – The Open Catalyst / Open Materials lineage (OC20/22, OMat24, OC25)
Strategy

The clearest thesis in the field: scale the data, then train one universal atomic model on top of it. Because the releases are open — commercial use included — academic groups are shifting from training their own models to fine-tuning or distilling these.

04NVIDIA — BioNeMo & Clara

NVIDIA — BioNeMo & Clara

platform · drug discovery
Platform
  • – NIM microservices that serve models like AlphaFold2, ESM-2, DiffDock, and MolMIM as APIs
  • – Blueprints — reference workflows for multi-step generative pipelines
  • Evo 2, a genome foundation model built with the Arc Institute
Strategy

A picks-and-shovels play. Rather than competing on benchmarks, NVIDIA sells the lab-in-the-loop flywheel — predict, synthesize, measure, retrain — and keeps the whole ecosystem running on its GPUs.

05D. E. Shaw Research

D. E. Shaw Research (DESRES)

physics-first · molecular dynamics
Tech & results
  • Anton 3 — a special-purpose MD supercomputer, roughly 100× faster than general-purpose hardware
  • – Physics as a data source: MD trajectories now train ML models such as diffusion cofolders
  • – Several candidates have reached clinical trials
Strategy

The clearest case of a physics-first approach reaching the clinic. Simulation is used to get around how scarce and expensive experimental data is — though here physics generates the data rather than acting as a constraint inside the learning objective.

06Xaira Therapeutics

Xaira Therapeutics

virtual cell · protein design
Flagship work
  • X-Atlas/Orion — one of the largest public Perturb-seq datasets, spanning every protein-coding gene
  • X-Cell — a multi-billion-parameter diffusion model for perturbation response, with zero-shot transfer to unseen cell types
  • – Antibody and binder design in the RFdiffusion / ProteinMPNN lineage
Strategy & debate

Spun out in 2024 from the David Baker / IPD lineage. It folds protein design, perturbation biology, foundation models, and wet-lab into one loop, and bets that biology has scaling laws too.

An open question — in 2025 benchmarks, several single-cell foundation models failed to beat even simple linear baselines at perturbation prediction. Whether they capture transferable biology or just interpolate well is still unsettled.

07ByteDance Seed

ByteDance Seed — AI for Science

protein · open · reproducible
Flagship models
  • Protenix — a fully open reproduction of AlphaFold 3 that matches or beats it under matched data and compute
  • DPLM — diffusion protein language models that co-generate sequence and structure
Strategy

Open, reproducible, benchmark-driven. Together with Tencent and DP Technology (Uni-Mol), it's part of a broad Chinese effort to compete with Western labs through open foundation models.

08Side by side

DeepMind / Isomorphic
Core axis: Structure prediction & design → everything · Flagship assets: AlphaFold 3, AlphaProteo · Openness: Free for academia / commercial exclusive
Microsoft Research
Core axis: Materials, DFT, protein dynamics · Flagship assets: MatterGen, BioEmu, Skala · Openness: Mostly open
Meta FAIR
Core axis: Atomistic simulation data & potentials · Flagship assets: OMol25, UMA · Openness: Open (incl. commercial)
NVIDIA
Core axis: Platform & infrastructure · Flagship assets: BioNeMo, NIM, Blueprints · Openness: Platform (commercial)
D. E. Shaw
Core axis: Physics (MD) & drug discovery · Flagship assets: Anton 3, MD synthetic data · Openness: Largely closed
Xaira
Core axis: Virtual cell & protein design · Flagship assets: X-Atlas/Orion, X-Cell · Openness: Partial data release
ByteDance Seed
Core axis: Protein foundation models · Flagship assets: Protenix, DPLM · Openness: Fully open

09Cross-cutting trends

1 · Consolidation

Task-specific models are giving way to universal ones — UMA, Evo 2, virtual cells.

2 · Data as moat

Proprietary data at scale (OMol25's 100M calculations, genome-wide Perturb-seq) is becoming the real barrier to entry.

3 · Lab-in-the-loop

Predict, synthesize, measure, retrain — where NVIDIA, Xaira, and MSR all converge.

4 · Agentic science

AI "scientists" that propose hypotheses and drive experiments — the theme of 2026.

10Open questions

A few things are still unsettled. How reproducible and genuinely useful large sets of generated candidates are — in materials or molecules — remains contested; a big prediction count isn't experimental value. Whether large biological foundation models learn transferable mechanism or just interpolate well is genuinely open. And most current work leans on scale, data, or physics-generated data; embedding a specific mechanism directly into the objective, or as a validation gate, is comparatively underexplored — a gap worth watching as the field matures.

11Deep dives

As I write closer reads of individual papers, they'll show up here:

  • Evo 2 — a DNA foundation model that reads and writes genomes across all of life read →
  • AlphaGenome — architecture and regulatory-track prediction (coming soon)
  • MatterGen — property-conditioned diffusion for crystals (coming soon)
  • BioEmu — emulating equilibrium ensembles (coming soon)

A living landscape post; details and links are current as of mid-2026 and will be updated.